Sanofi, BioNTech ink cancer immunotherapy agreement

Wednesday, November 4, 2015

BioNTech, a Mainz, Germany-based immunotherapy provider, have entered into a multiyear exclusive collaboration and license agreement to leverage the scientific expertise of the two organizations to discover and develop up to five cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).

[Read More]

Vaccine Center of Innovation launches

Thursday, October 22, 2015

In an effort to accelerate timelines and decrease development costs of life-saving vaccines, the Infectious Disease Research Institute (IDRI) and Sanofi Pasteur have established the Global Health Vaccine Center of Innovation (GHVCI), to be based at IDRI in Seattle. The project is funded in part by a grant from the Bill & Melinda Gates Foundation. The GHVCI represents an alliance among the three organizations, focused on accelerating the development of vaccines and associated technologies to fight a wide range of global infectious diseases, and ensuring that those critical vaccines are accessible globally, especially to people in need within developing countries.

[Read More]

International diabetes research knowledge portal opens

Thursday, October 8, 2015

Researchers funded by the NIH and the Foundation for the NIH (FNIH) have expanded a recently launched online library, called a knowledge portal, which allows open-access searching of human genetic and clinical information on type 2 diabetes. Individual data will remain confidential. The portal includes information from several major international networks, collected from decades of research.

[Read More]

DREAM Challenge winners announced

Wednesday, September 23, 2015

Winners have been announced for the Prostate Cancer DREAM Challenge, the first research challenge in prostate cancer to marry crowdsourcing with data sharing, paving a new way to tackle key research questions about metastatic castration-resistant prostate cancer (mCRPC), an advanced form of the disease with poor outcomes.

[Read More]

PeptiDream, Sanofi collaborate

Monday, September 14, 2015

PeptiDream, a public Tokyo-based biopharmaceutical company, has announced a multi-target discovery and optimization collaboration with Sanofi. PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi. Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.

[Read More]